Executive Summary
The USA Bankruptcy & Insolvency stream features a single high-materiality (10/10) filing from Cannabist Co Holdings Inc., signaling acute distress in the cannabis sector with initiation of CCAA proceedings in Canada and planned Chapter 15 in the US to enable asset sales and orderly wind-down. Operations have ceased in New York and are ceasing in Pennsylvania, amid persistent operational challenges, with trading halt and delisting review imminent. Key asset divestitures include a closed $130M Virginia sale, pending $16.5M Delaware cash deal (Q2 2026 close), $47M Ohio sale ($34.5M cash + $12.5M note, Q3 2026 close), and a non-binding MOU for remaining assets in six states. Supporting noteholders (>60% of 9.25% Senior Secured Notes due 2028 and 9.0% Convertible Notes due 2028) endorse transactions, providing some creditor backing but underscoring equity wipeout risk. No period-over-period financial trends available, but operational contractions highlight deteriorating performance. Market implications include zero equity value potential, distressed asset opportunities, and broader cannabis sector contagion risks.
Tracking the trend? Catch up on the prior US Bankruptcy Chapter 11 Insolvency SEC Filings digest from March 20, 2026.
Investment Signals(12)
- Cannabist↓(BEARISH)▲
Initiated CCAA proceedings with 10-day initial stay (extendable) and planned US Chapter 15 for wind-down, ceasing ops in NY/PA
- Cannabist↓(BEARISH)▲
Trading halt and delisting review anticipated post-filing, erasing liquidity for shareholders
- Cannabist↓(BEARISH)▲
Persistent operational challenges cited, with ops cessation in two states signaling irreversible decline
- Cannabist↓(BEARISH)▲
>60% noteholders (9.25% Senior Secured Notes due 2028, 9.0% Convertible Notes due 2028) support asset sales, prioritizing debt recovery over equity
- Cannabist↓(BEARISH)▲
Recent $130M Virginia sale closed, but structured as distress divestiture amid insolvency
- Cannabist↓(BEARISH)▲
Delaware assets sale for $16.5M cash pending Q2 2026 close, below potential standalone value in healthier markets
- Cannabist↓(BEARISH)▲
Ohio ops sale for $47M ($34.5M cash + $12.5M note) closing Q3 2026, reflecting fire-sale pricing
- Cannabist↓(BEARISH)▲
Non-binding MOU for six-state assets, but subject to court approval in insolvency process
- Cannabist↓(BEARISH)▲
FTI Consulting appointed as CCAA Monitor, standard for restructurings but flags control loss
- Cannabist↓(BEARISH)▲
Negative sentiment across filing with no forward growth guidance, only wind-down timeline
- Cannabist↓(BEARISH)▲
No insider buying or positive capital allocation signals; focus solely on creditor-backed liquidation
- Cannabist↓(BEARISH)▲
Equity holders face total loss as proceeds directed to noteholders first
Risk Flags(10)
- Cannabist/Insolvency Proceedings↓[HIGH RISK]▼
CCAA initiated with Chapter 15 planned, enabling asset sales but risking full equity dilution
- Cannabist/Operational Shutdown↓[HIGH RISK]▼
Ceased NY ops, ceasing PA ops, with no reversal indicated amid challenges
- Cannabist/Delisting Risk↓[HIGH RISK]▼
Trading halt imminent, delisting review underway, destroying shareholder access
- Cannabist/Creditor Priority↓[HIGH RISK]▼
>60% noteholders back deals, but leaves no recovery path for common equity
- Cannabist/Deal Execution↓[MEDIUM RISK]▼
Delaware $16.5M close Q2 2026, Ohio $47M Q3 2026 at risk of delays/non-closure in bankruptcy
- Cannabist/MOU Uncertainty↓[MEDIUM RISK]▼
Non-binding term sheet for six states, vulnerable to bids or court rejection
- Cannabist/Stay Extension↓[MEDIUM RISK]▼
Initial 10-day CCAA stay extendable, prolonging uncertainty and potential challenges
- Cannabist/Liquidity Crunch↓[HIGH RISK]▼
No capital allocation (dividends/buybacks) mentioned, ops wind-down accelerates cash burn
- Cannabist/Sector Contagion↓[HIGH RISK]▼
Cannabis peer distress implied by 'persistent challenges,' no YoY/QoQ recovery trends
- Cannabist/No Guidance↓[HIGH RISK]▼
Zero forward-looking ops growth; only liquidation timeline provided
Opportunities(8)
- Cannabist/Noteholder Recovery↓(OPPORTUNITY)◆
>60% supporting noteholders positioned for partial recovery via $47M Ohio + $16.5M Delaware sales
- Cannabist/Delaware Assets↓(OPPORTUNITY)◆
$16.5M cash sale closing Q2 2026 offers buyer cheap entry to cannabis assets in orderly process
- Cannabist/Ohio Divestiture↓(OPPORTUNITY)◆
$47M deal ($34.5M cash upfront) Q3 2026 undervalued vs prior $130M Virginia sale benchmark
- Cannabist/MOU Assets↓(OPPORTUNITY)◆
Non-binding deal for six states could attract competitive bids in CCAA auction process
- Cannabist/Distressed Debt↓(OPPORTUNITY)◆
9.25%/9.0% Notes due 2028 backed by >60% holders, trade at deep discount pre-recovery
- Cannabist/Asset Buyers↓(OPPORTUNITY)◆
Fire-sale pricing on ops in multiple states amid wind-down creates M&A alpha for acquirers
- Cannabist/Monitor Oversight↓(OPPORTUNITY)◆
FTI Consulting role ensures transparent sales, reducing execution risk for participants
- Cannabist/Short Equity↓(OPPORTUNITY)◆
Pre-delisting trading halt offers final window for shorts on zero-value stock
Sector Themes(6)
- Cannabis Insolvency Acceleration(BEARISH SECTOR IMPACT)◆
Single filing shows ops cessation in key states (NY/PA), signaling 100% of covered firms in wind-down mode with no YoY recovery
- Distressed Asset Sales Pattern(BUYER OPPORTUNITY)◆
$193.5M total deals ($130M closed + $63.5M pending) at blended ~$40-50M/state pricing, undervalued vs operating multiples
- Creditor Control Dominance◆
>60% noteholder support standard in cannabis restructurings, prioritizing secured debt over equity (100% equity risk in sample) [DEBT BULLISH, EQUITY BEARISH]
- Wind-Down Timelines[TIME-SENSITIVE RISK]◆
Q2/Q3 2026 closings cluster post-CCAA, creating near-term catalysts but prolonging delisting/liquidity loss
- Operational Contraction(SECTOR WEAKNESS)◆
Ceasing multi-state ops reflects margin collapse/no growth trends, with negative sentiment 100% across filings
- No Capital Returns(FINANCIAL DISTRESS THEME)◆
Zero dividends/buybacks/splits; all cash to creditors, contrasting healthy sectors' reinvestment
Watch List(8)
- Cannabist/CCAA Stay Extension↓(CRITICAL)👁
Monitor court hearing post-10-day initial stay (~April 3, 2026) for extension approval
Track Q2 2026 closing of $16.5M cash deal for execution risks/delays [Q2 2026]
Watch Q3 2026 $47M Ohio deal ($34.5M cash + note) amid noteholder support [Q3 2026]
- Cannabist/MOU Progress↓(NEAR-TERM)👁
Non-binding six-state MOU developments, potential auctions/bids in CCAA process
- Cannabist/Trading Halt↓(IMMEDIATE)👁
Imminent halt and delisting review timeline from exchange notifications
- Cannabist/Chapter 15 Filing↓(UPCOMING)👁
US ancillary proceedings initiation post-CCAA for asset sales recognition
- Cannabist/Noteholder Actions↓(ONGOING)👁
Further support or challenges from remaining <40% noteholders
Initial Monitor reports on asset values/creditor distributions [10-30 DAYS]
Filing Analyses(1)
24-03-2026
The Cannabist Company has initiated CCAA proceedings in Canada and plans Chapter 15 in the US to facilitate asset sales and orderly wind-down, including ceasing operations in New York and Pennsylvania, with trading halt and delisting review anticipated. It entered definitive agreements to sell Ohio operations for $47M ($34.5M cash + $12.5M note, closing Q3 2026) and Delaware assets for $16.5M cash (closing Q2 2026), following the closed $130M Virginia sale; a non-binding MOU covers remaining markets in six states. Supporting noteholders (>60% of Notes) back the transactions amid persistent operational challenges.
- ·Supporting Noteholders hold >60% of 9.25% Senior Secured Notes due Dec 31, 2028 and 9.0% Senior Secured Convertible Notes due Dec 31, 2028.
- ·Initial CCAA stay of proceedings for 10 days, extendable; FTI Consulting as Monitor.
- ·Operations ceased in New York; ceasing in Pennsylvania.
- ·Subsidiaries operate in 10 U.S. jurisdictions.
Get daily alerts with 12 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)